Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 8, 2012, Pages

  Morrison, Jo ^a   Haldar, Krishnayan ^b   Kehoe, Sean ^c   Lawrie, Theresa A ^d  

^a MUSGROVE PARK HOSPITAL   (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d ROYAL UNITED HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; PACLITAXEL;

ADJUVANT THERAPY; ADVANCED CANCER; AGE; CANCER CHEMOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CYTOREDUCTIVE SURGERY; HISTOPATHOLOGY; HUMAN; MULTICENTER STUDY (TOPIC); NEOADJUVANT CHEMOTHERAPY; OPERATIVE BLOOD LOSS; OVARY CARCINOMA; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; ADJUVANT CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; METHODOLOGY; MORTALITY; OVARY TUMOR; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84866763346     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005343.pub3     Document Type: Review

References (111)

1. Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. European Journal of Cancer 2011;47(Suppl 3):S88-91.
2. Vergote I, Pecorelli S, Stuart G. Intergroup Study (EORTC 55971/NCIC OV13). Randomized Phase III study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with Stage IIIc or IV epithelial ovarian carcinoma. Trial protocol: http://www.cancer.gov/clinicaltrials/EORTC-55971 2003 (accessed 17 June 2012).
3. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al.Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine 2010;363(10):943-53. [Incl. Supplementary Appendix and Protocol].
4. Vergote I, Tropé CG, Amant F, Ehlen T, Reed NS, Casado A. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. Journal of Clinical Oncology 2011;29(31):4076-8.
5. Verleye L, Ottevanger PB, Kristensen GB, Ehlen T, Johnson N, van der Burg ME, et al.Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. European Journal of Cancer 2011;47(1):57-64.
6. Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, et al.Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer 2001;91(12):2329-34.
7. Baekelandt M. The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. International Journal of Gynecological Cancer 2003;13 Suppl 2:163-8.
8. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecologic Oncology 1990;38(2):203-9.
9. Bidzinski M, Danska-Bidzinska A, Ziólkowska-Seta I, Derlatka P, Sobiczewski P, Raczynski P. Analysis of the treatment of ovarian cancer patients with neo-adjuvant chemotherapy - preliminary results. European Journal of Gynaecological Oncology 2005;26(4):423-6.
10. Bristow R, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival impact of maximum cytoreductive surgery for advanced ovarian carcinoma during the platinum-era: a meta-analysis of 6, 848 patients. Proceedings of the American Society of Clinical Oncology. 2001; Vol. 20:(Abstract 807) 202a.
11. Chambers JT, Chambers SK, Voynick IM, Schwartz PE. Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecologic Oncology 1990;37(3):327-31.
12. Chan YM, Ng TY, Ngan HY, Wong LC. Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecologic Oncology 2003;88(1):9-16.
13. Colombo P-E, Mourregot A, Fabbro M, Gutowski M, Saint-Aubert B, Quenet F, et al.Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. The Journal of Cancer Surgery 2009;35:135-43.
14. Deval BPJ, Platini C, Combe M, Boiron C, Mignot L, Geay J, et al.Surgery: an option for patients with FIGO stage IV ovarian cancer treated by platinum-paclitaxel-based regimen? A GINECO study. Proceedings of the American Society of Clinical Oncology. 2003; Vol. 22:452; Abstract 1817.
15. Dutta T, Sharma H, Kumar L, Dinda AK, Kumar S, Bhatla N, et al.Neoadjuvant chemotherapy for epithelial ovarian cancer - role of apoptosis. Cancer Chemotherapy and Pharmacology 2005;56(4):427-35.
16. Evdokimova NI, Grigorova TM. [Comparative study of 2 combined treatment regimens in stage-III to -IV ovarian cancer]. Voprosy Onkologii 1982;28(7):28-34.
17. Everett EN, French AE, Stone RL, Pastore LM, Jazaeri AA, Andersen WA. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. American Journal of Obstetrics and Gynecology 2006;195(2):574-6.
18. Fanfani F, Ferrandina G, Corrado G, Fagotti A, Zakut HV, Mancuso S, et al.Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology 2003;65(4):316-22.
19. Feng Y, Sun T. Short-term effects of chemotherapy-surgery-chemotherapy regimen on clinically inoperable advanced ovarian cancer. Chinese Medical Journal 1998;111(8):722-5.
20. Ghaemmaghami F, Karimi-Zarchi M, Modares-Gilani M, Mousavi A, Behtash N. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery. Asia Pacific Journal of Cancer Prevention 2008;9(4):719-24.
21. Giannopoulos T, Butler-Manuel S. Clinical outcomes of neoadjuvant chemotherapy and primary debulking surgery in advanced ovarian carcinoma. European Journal of Gynaecological Oncology 2006;27(1):25-8.
22. Hanker LCP. Complete surgical debulking in advanced ovarian carcinoma improves prognosis in any FIGO stage: analysis of 3, 126 prospectively randomized patients in AGO-OVAR/GINECO phase 3 trials. Archives of Gynecology and Obstetrics; 58th Congress of the German Society for Gynecology and Obstetrics (Deutsche Gesellschaft fur Gynakologie und Geburtshilfe, DGGG. October 2010; Vol. 282.
23. Hegazy MA, Hegazi RA, Elshafei MA, Setit AE, Elshamy MR, Eltatoongy M, et al.Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World Journal of Surgical Oncology 2005;3:57.
24. Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, et al.Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecological Oncology 2007;105(1):211-7.
25. Inciura A, Simavicius A, Juozaityte E, Kurtinaitis J, Nadisauskiene R, Svedas E, et al.Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients. BMC cancer 2006;6:153.
26. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecologic Oncology 1991;42(2):146-50.
27. Kayikcioglu F, Kose MF, Boran N, Ozdas E, Ozgul N, Tulunay G. Neoadjuvant chemotherapy in advanced stage ovarian carcinoma. VIII Meeting of the International Gynecologic Cancer Society. Buenos Aires, Argentina, 2000:Abstract 48.
28. Kayikcioglu F, Kose MF, Boran N, Caliskan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. International Journal of Gynecological Cancer 2001;11(6):466-70.
29. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, et al.Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC Ovarian Carcinoma. Cancer 2001;92(10):2585-91.
30. Lawton FG, Redman CW, Luesley DM, Chan KK, Blackledge G. Neoadjuvant (cytoreductive) chemotherapy combined with intervention debulking surgery in advanced, unresected epithelial ovarian cancer. Obstetrics and Gynecology 1989;73(1):61-5.
31. Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. Journal of Obstetric and Gynaecological Research 2006;32(1):99-106.
32. Lim JT, Green JA. Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clinical Oncology (Royal College of Radiologists (Great Britain)) 1993;5(4):198-202.
33. Liu S, Jiang D, Xu G. Advanced ovarian cancer: combination chemotherapy and cytoreductive surgery. Acta Academiae Medicinae Hubei 1995;16(4):343-4.
34. Liu EL, Mi RR. Neoadjuvant intraarterial chemotherapy and embolization in treatment of advanced ovarian epithelial carcinoma. Chinese Medical Journal (Engl) 2004;117(10):1547-51.
35. Loizzi V, Cormio G, Resta L, Rossi CA, Di Gilio AR, Cuccovillo A, et al.Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. International Journal of Gynecological Cancer 2005;15(2):217-23.
36. Lotze W, Richter P, Sarembe B. [Intra-arterial chemotherapy in advanced ovarian cancers. 2. Therapeutic results in relation to prognostic factors]. Zentralblatt für Gynäkologie 1987;109(9):578-85.
37. Lyngstadaas A, Ekanger R, Hagen B, Himmelmann A, Iversen OE, Iversen T, et al.[Primary treatment of ovarian cancer]. Tidsskrift for den Norske Laegeforening 2005;125(3):278-81.
38. Mackay HJP. Phase II/III study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: NCIC CTG OV.21. Current Oncology 2011;18(2):84-90.
39. Mahner S, Park TW, Ortmann O, Hilfrich J, Breitbach GP, Höss C, et al.Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer. A randomized multicenter phase II study (PRIMOVAR). International Journal of Gynecological Cancer 2006;16(S3):659.
40. Malzoni M, Palagiano A, Palmese A. Neo-adjuvant chemotherapy in ovarian carcinoma (case report). Rassegna Internazionale di Clinica e Terapia 1993;73(7):309-12.
41. Mazzeo F, Berliere M, Kerger J, Squifflet J, Duck L, D'Hondt V. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecologic Oncology 2003;90(1):163-9.
42. Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C, et al.Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. Journal of the American College of Surgeons 2003;197(6):955-63.
43. Negretti E, Zambetti M, Luciani L, Gianni L. Timing of surgery and the role of cytoreductive chemotherapy in patients with advanced ovarian carcinoma. Tumori 1988;74(5):567-72.
44. Oe S, Hasegawa K, Ichikawa R, Torii Y, Kato R, Komiyama S, et al.[Treatment outcomes for advanced ovarian cancers with peritoneal dissemination]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 2011;38(4):591-7.
45. Onda T, Kobayashi H, Nakanishi T, Hatae M, Iwasaka T, Konishi I, et al.Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecologic Oncology 2009;113(1):57-62.
46. Onnis A, Marchetti M, Padovan P, Castellan L. Neoadjuvant chemotherapy in advanced ovarian cancer. European Journal of Gynaecologic Oncology 1996;17(5):393-6.
47. Polcher M, Mahner S, Ortmann O, Hilfrich J, Diedrich K, Breitbach GP, et al.Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer - a prospective multicenter phase II trial (PRIMOVAR). Oncology Reports 2009;22(3):605-13.
48. Rafii A, Deval B, Geay JF, Chopin N, Paoletti X, Paraiso D, et al.Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study. International Journal of Gynecological Cancer 2007;17(4):777-83.
49. Recchia F, De Filippis S, Rosselli M, Saggio G, Carta G, Rea S. Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. European Journal of Gynaecological Oncology 2001;22(4):287-91.
50. Redman CW, Warwick J, Luesley DM, Varma R, Lawton FG, Blackledge GR. Intervention debulking surgery in advanced epithelial ovarian cancer. British Journal of Obstetrics and Gynaecology 1994;101(2):142-6.
51. Robova H, Rob L, Pluta M, Kacirek J, Strnad P, Schlegerova D. Neoadjuvant chemotherapy in patients with primary unresectable ovarian cancer. International Journal of Gynecological Cancer. 2003; Vol. 13 (Suppl 1):44.
52. Salzer H, Genger H, Gober S, Barrada M, Vavra N, Sevelda P. [Surgery in the treatment concept of epithelial ovarian cancer]. Gynäkologische Rundschau 1990;30 Suppl 1:26-9.
53. Schwartz PE, Chambers JT, Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecologic Oncology 1994;53(1):33-7.
54. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecologic Oncology 1999;72(1):93-9.
55. Shibata K, Kikkawa F, Mika M, Suzuki Y, Kajiyama H, Ino K, et al.Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: survival benefit and prognostic factors. International Journal of Gynecological Cancer 2003;13(5):587-92.
56. Shimizu Y, Hasumi K. [Treatment of stage III and IV ovarian cancer - is neoadjuvant chemotherapy effective?]. Nippon Sanka Fujinka Gakkai Zasshi 1993;45(9):1007-14.
57. Steed H, Oza AM, Murphy J, Laframboise S, Lockwood G, DE Petrillo D, et al.A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer. International Journal of Gynecological Cancer 2006;16(Suppl 1):47-53.
58. Sun T, Feng Y, Zhu Y, Zheng Y. Therapeutic strategy in the management of stage II - IV epithelial ovarian carcinoma. Chinese Medical Journal 2000;113(7):625-7.
59. Surwit E, Childers J. Cytoreductive surgery in advanced ovarian cancer with or without neoadjuvant chemotherapy. Gynecologic Oncology 1999;72(3):468.
60. Trope C. Primary debulking surgery is not an independent prognostic factor in advanced stage IIIC ovarian carcinoma. Gynecologic Oncology 1997;64(2):357.
61. Ushijima K, Ota S, Komai K, Matsuo G, Motoshima S, Honda S, et al.Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. International Surgery 2002;87(3):185-90.
62. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al.The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. New England Journal of Medicine 1995;332(10):629-34.
63. Vergote I, De Wever IW, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecologic Oncology 1998;71(3):431-6.
64. Vergote IB, De Wever I, Decloedt J, Tjalma W, Van Gramberen M, van Dam P. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Seminars in Oncology 2000;27(3 Suppl 7):31-6.
65. Vrscaj MU, Rakar S. Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study. European Journal of Gynaecological Oncology 2002;23(5):405-10.
66. Kehoe S, Wheeler S. CHORUS (Chemotherapy or Upfront Surgery). A randomised feasibility trial to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. www.ctu.mrc.ac.uk/plugins/StudyDisplay/protocols/CHORUS protocol Version 2.0 - 05 June 2008.pdf; and http://www.ctu.mrc.ac.uk/research_areas/study_details.aspx?s=9. London, (accessed 18/6/2012).
67. Law K, Murray C, Kehoe S. CHORUS - a randomised study to determine the impact of timing of surgery and chemotherapy in newly diagnosed patients with advanced epithelial ovarian, primary peritoneal or fallopian tube carcinoma. Proceedings of the Annual Meeting of the British Gynaecological Cancer Society; 2006: Nov 30-Dec 1; Manchester, UK 90.
68. Janga D, Kumar L, Kumar S, Shukla NK, Thulkar S, Singh R. Neoadjuvant chemotherapy (CT) followed by debulking surgery vs upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma (EOC): a prospective, randomized study. Proceedings of the American Society of Clinical Oncology. 2003; Vol. 22:487.
69. Kumar L, Hariprasad R, Kumar S, Bhatla N, Shukla N, Thulkar S, et al.Neoadjuvant chemotherapy in advanced epithelial ovarian cancer (EOC): a phase III randomized study. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I (June 20 Supplement). 2006; Vol. 24:18 Suppl.
70. Kumar L, Hariprasad R, Kumar S, Bhatla N, Thulkar S, Shukla NJ. Neo-adjuvant chemotherapy in advanced epithelial ovarian cancer (EOC): a prospective, randomized study. Indian Journal of Medical and Paediatric Oncology 2009;30(1):15.
71. Kumar L, Hariprasad R, Kumar S, Bhatla N, Thulkar S, Vijayaraghavan M. Neoadjuvant chemotherapy followed by interval debulking surgery versus upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma: a prospective randomized study - interim results. Journal of Clinical Oncology; ASCO Annual Meeting Proceedings Part I. Chicago, Illinois, 2007; Vol. 25(18 Suppl):5531.
72. Kumar L, Hariprasad R, Kumar S, Bhatla N, Thulkar S, Vijayaraghavan M, et al.Neoadjuvant chemotherapy followed by interval debulking surgery versus upfront surgery followed by chemotherapy in advanced epithelial ovarian carcinoma: a prospective randomized study - interim results. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement). 2007:5531.
73. Kumar L, Janga D, Berge S, Gupta S, Kumar S, Bhatla N, et al.Neoadjuvant chemotherapy in stage III & IV epithelial ovarian carcinoma (EOC). Journal International Medical Sciences Academy 2003;16(2):89-92.
74. Onda T, Matsumoto K, Shibata T, Sato A, Fukuda H, Konishi I, et al.Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602. Japanese Journal of Clinical Oncology 2008;38(1):74-7.
75. Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. European Journal of Gynaecologic Oncology 1995;16(5):349-56.
76. Ang C, Chan KKL, Bryant A, Naik R, Dickinson HO. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD007697.pub2].
77. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of Clinical Oncology 2002;20(5):1248-59.
78. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecologic Oncology 2006;103(3):1070-6.
79. Bristow RE, Eisenhauer EL, Santillan A, Chi DS. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecologic Oncology 2007;104:480-90.
80. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecologic Oncology 1991;40(2):103-6. [MEDLINE: 91184633].
81. Chi D. An analysis of patients with bulky stage IIIC/IV ovarian, tubal and peritoneal carcinoma treated with primary debulking surgery (PDS) during the same period as the randomized EORTC-NCIC trial of PDS versus neoadjuvant chemotherapy. Gynecologic Oncology Conference: 41st Annual Meeting of the Society of Gynecologic Oncologists; 2010 Mar 14-17, 2010. San Francisco, CA, 2010.
82. Chi D, Bristow RE, Armstrong DK, Karlan BY. Is the easier way ever the better way?. Journal of Clinical Oncology 2011;29(31):4073-5.
83. U.S. Department fo Health and Human Services. Common terminology criteria for adverse events (CTCAE) Version 4.03. National Cancer Institute June 14, 2010:1-196.
84. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
85. Dewdney SB, Rimel BJ, Reinhart AJ, Kizer NT, Brooks RA, Massad LS, et al.The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. Gynecologic Oncology 2010;119(1):18-21.
86. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized Phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire(GINECO). Cancer 2009;115(6):1234-44.
87. du Bois A, Marth C, Pfisterer J, Harter P, Hilpert F, Zeimet AG, et al.Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer. International Journal of Gynecological Cancer 2011;21(6):1165-8.
88. Sant M, Aareleid T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, et al.and the EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Annals of Oncology 2003;14(Suppl 5):v61-118.
89. FIGO Committee in Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. International Journal of Gynecology and Obstetrics 2009;105:3-4.
90. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer incidence and mortality worldwide: Lyon, France: International Agency for Research on Cancer. IARC CancerBase No. 10; 2008. globocan.iarc.fr Vol. (accessed 17 June 2012).
91. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. National Cancer Institute Monograph 1975;42:101-4. [MEDLINE: 77056303].
92. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
93. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecologic Oncology 1992;47(2):159-66. [MEDLINE: 93106491].
94. Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?. American Journal of Obstetrics and Gynecology 1992;166(2):504-11. [MEDLINE: 92160883].
95. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al.Cancer statistics. CA: A Cancer Journal for Clinicians 2008;58:71-96.
96. Kang S, Nam BH. Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies. Annals of Surgical Oncology 2009;16(8):2315-20.
97. Kehoe S, Powell J, Wilson S, Woodman C. The influence of the operating surgeon's specialisation on patient survival in ovarian carcinoma. British Journal of Cancer 1994;70(5):1014-7.
98. Kumar L, Hariprasad R, Kumar S, Bhatla N, Thulkar S, Shukla NJ. Neo-adjuvant chemotherapy in advanced epithelial ovarian cancer (EOC): a prospective, randomized study. Indian Journal of Medical and Paediatric Oncology 2009;30(1):15.
99. Onda T, Yoshikawa H, Yasugi T, Matsumoto K, Taketani Y. The optimal debulking after neoadjuvant chemotherapy in ovarian cancer: proposal based on interval look during upfront surgery setting treatment. Japanese Journal of Clinical Oncology 2010;40(1):36-41.
100. Onda T, Yoshikawa H. Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions. Expert Reviews in Anticancer Therapy 2011;11(7):1053-67.
101. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34. [MEDLINE: 99120172].
102. Petru E, Pickel H, Tamussino K, Lahousen M, Heydarfadai M, Posawetz W, et al.Pretherapeutic scalene lymph node biopsy in ovarian cancer. Gynecologic Oncology 1991;43(3):262-4. [MEDLINE: 92090796].
103. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
104. Swart PE. Contemporary considerations for neoadjuvant chemotherapy in primary ovarian cancer. Current Oncology Reports 2009;11:457-65.
105. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P, Bryant A. Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2010, Issue 10. [DOI: 10.1002/14651858.CD006014.pub5].
106. Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, et al.First-line therapy in ovarian cancer trials. International Journal of Gynecological Cancer 2011;21(4):756-62.
107. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo, N, et al.International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. Journal of the National Cancer Institute 2003;95(2):105-12.
108. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al.Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK collaborative trial of ovarian cancer screening (UKCTOCS). The Lancet Oncology 2009;10(4):327-40.
109. Vergote I, Tropé CG, Amant F, Ehlen T, Reed NS, Casado A. Neoadjuvant chemotherapy is the better treatment option in some patients with stage IIIc to IV ovarian cancer. Journal of Clinical Oncology 2011;29(31):4076-8.
110. Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. European Journal of Cancer 2011;47(Suppl 3):S88-91.
111. Morrison J, Swanton A, Collins S, Kehoe S. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005343.pub2].